Brief: Relief Therapeutics: Collaboration Partner Resubmits Acer-001 (Sodium Phenylbutyrate) New Drug Application (NDA) To FDA

MindMaze Therapeutics Holding SA

18/07/2022 06:19

July 18 (Reuters) - RELIEF THERAPEUTICS HOLDING SA  RLFB.S :
    * RELIEF THERAPEUTICS ANNOUNCES THAT ITS COLLABORATION
PARTNER HAS
RESUBMITTED THE ACER-001 (SODIUM PHENYLBUTYRATE) NEW DRUG
APPLICATION (NDA) TO THE FDA FOR THE TREATMENT OF UREA CYCLE
DISORDERS (UCDS)

Source text for Eikon:  ID:nEQbbnV2Za 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))